Furthermore, the phase II trial of margetuximab, an Fc-optimized, anti-HER2 monoclonal antibody with increased affinity, demonstrated favorable results when combined with pembrolizumab with ORR of 24% and DCR of 62% in AGC patients with HER2 IHC3+ tumor in a second-line setting [65]. The gene discussed is ERBB2; the disease is neoplasm.